US 12,433,931 B2
Lisinopril formulations
Gerold L. Mosher, Kansas City, MO (US); and David W. Miles, Kansas City, MO (US)
Assigned to AZURITY PHARMACEUTICALS, INC., Woburn, MA (US)
Filed by Azurity Pharmaceuticals, Inc., Woburn, MA (US)
Filed on Dec. 13, 2024, as Appl. No. 18/979,962.
Application 18/979,962 is a continuation of application No. 18/663,349, filed on May 14, 2024, granted, now 12,186,360.
Application 18/663,349 is a continuation of application No. 18/450,553, filed on Aug. 16, 2023, granted, now 12,128,083, issued on Oct. 29, 2024.
Application 18/450,553 is a continuation of application No. 17/507,144, filed on Oct. 21, 2021, granted, now 11,771,733, issued on Oct. 3, 2023.
Application 17/507,144 is a continuation of application No. 17/194,021, filed on Mar. 5, 2021, granted, now 11,179,434, issued on Nov. 23, 2021.
Application 17/194,021 is a continuation of application No. 16/822,412, filed on Mar. 18, 2020, granted, now 10,940,177, issued on Mar. 9, 2021.
Application 16/822,412 is a continuation of application No. 16/564,904, filed on Sep. 9, 2019, abandoned.
Application 16/564,904 is a continuation of application No. 16/295,482, filed on Mar. 7, 2019, granted, now 10,406,199, issued on Sep. 10, 2019.
Application 16/295,482 is a continuation of application No. 16/053,164, filed on Aug. 2, 2018, granted, now 10,265,370, issued on Apr. 23, 2019.
Application 16/053,164 is a continuation of application No. 15/805,934, filed on Nov. 7, 2017, granted, now 10,039,800, issued on Aug. 7, 2018.
Application 15/805,934 is a continuation of application No. 15/483,691, filed on Apr. 10, 2017, granted, now 9,814,751, issued on Nov. 14, 2017.
Application 15/483,691 is a continuation of application No. 15/268,095, filed on Sep. 16, 2016, granted, now 9,616,096, issued on Apr. 11, 2017.
Application 15/268,095 is a continuation of application No. 14/934,752, filed on Nov. 6, 2015, granted, now 9,463,183, issued on Oct. 11, 2016.
Claims priority of provisional application 62/249,011, filed on Oct. 30, 2015.
Prior Publication US 2025/0186533 A1, Jun. 12, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/05 (2006.01); A61K 9/00 (2006.01); A61K 31/401 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01)
CPC A61K 38/05 (2013.01) [A61K 9/0053 (2013.01); A61K 9/0095 (2013.01); A61K 31/401 (2013.01); A61K 38/005 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01)] 29 Claims
 
1. A method of treating hypertension in a subject comprising administering to that subject a therapeutically effective amount of a stable oral liquid formulation, comprising:
(i) lisinopril or a pharmaceutically acceptable salt or solvate thereof;
(ii) a preservative selected from the group consisting of sodium benzoate, benzoic acid, sorbic acid, methylparaben, ethylparaben, propylparaben, butylparaben, and pharmaceutically acceptable salts thereof;
(iii) a liquid vehicle, wherein the liquid vehicle comprises water; and
(iv) optionally a sweetener;
wherein the formulation is stable at about 25±5° C. for at least 6 months.